Sanofi American Depositary Shares (Each representing one-half of one ordinary share) SNY

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Con 25 acciones de SNY (USD 984,28) habrías recibido USD 60,50 en dividendos en los últimos 12 meses.

• Zacks Investment Research 2 oct

  Sanofi, Regeneron Expand Immunology Alliance With New Antibodies

  Sanofi and Regeneron have expanded their longstanding alliance to co-develop four next-generation long-acting antibodies targeting type II inflammation. Regeneron will receive $1 billion upfront and up to $7 billion in milestone payments, with both companies equally sharing development costs and future profits. The collaboration builds on their successful Dupixent partnership, which generated €9.3 billion in sales in H1 2026 and is projected to reach €25 billion by 2030.

  

• Zacks Investment Research 29 sept

  GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?

  GSK and Sanofi, two major European pharmaceutical companies, are compared across growth drivers, pipelines, and valuations. GSK shows strong specialty medicines growth (14% in H1 2026) with expanding oncology and HIV franchises, while Sanofi benefits from blockbuster Dupixent sales (up 28.6%) and stronger near-term earnings growth. Despite both holding Hold ratings, Sanofi appears better positioned due to superior earnings growth outlook, favorable valuation metrics, and positive estimate revisions, though it faces vaccine sales headwinds and heavy Dupixent reliance.

  

• GlobeNewswire Inc. 25 sept

  Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - SNS Insider

  The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD 12.24 billion in 2025 to USD 27.90 billion by 2035, with a CAGR of 8.59%. Growth is driven by early identification of rare lysosomal storage disorders, increased newborn screening, orphan drug incentives, and expanding healthcare access. North America leads with 38.76% market share, while Asia-Pacific shows the fastest growth at 9.43% CAGR. Imiglucerase dominates products, and Gaucher disease represents the largest therapeutic condition.

  

• The Motley Fool 22 sept

  Is Regeneron Stock a Bargain Below $800?

  Regeneron Pharmaceuticals' stock has declined from over $1,000 to below $800 over the past two years, primarily due to challenges with its Eylea product facing biosimilar competition. However, the company shows strong fundamentals with 17% revenue growth driven by Dupixent, successful mitigation of Eylea losses through its HD formulation, and promising pipeline candidates including the weight-loss drug olatorepatide. The analyst views the stock as attractive at current levels given its long-term growth prospects and shareholder return programs.

  

• GlobeNewswire Inc. 22 sept

  Recludix Pharma to Present at the Oppenheimer Private Life Sciences Company Showcase

  Recludix Pharma, a clinical-stage biotech company focused on inflammatory disease treatments, announced that its CEO and head of R&D will present at the Oppenheimer Private Life Sciences Company Showcase on September 29, 2026. The company is developing STAT6 and BTK inhibitors in partnership with Sanofi, with a Phase 1 study underway for REX-8756 targeting diseases like atopic dermatitis and asthma.